A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007)

A Double-Blind, Multicenter, Randomized, Titrated-Dose, Placebo-Controlled, Study of MK0364 (4 mg to 8 mg) in Chronic Cigarette Smokers as an Aid for Smoking Cessation

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00109135

Enrollment

300

Registered

2005-04-25

Start date

2005-01-31

Completion date

2005-06-30

Last updated

2015-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking

Brief summary

The purpose of this study is to evaluate the safety and tolerability of an investigational drug that may help individuals to stop smoking.

Interventions

DRUGtaranabant

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Smoking greater than/equal to 10 cigarettes/day for at least 1 year * Laboratory tests that meet the criteria of the study * In overall good health as determined by the investigator

Exclusion criteria

* Psychiatric diagnoses * Certain cancers * Patients who use nicotine replacement therapy * Patients on a diet regimen

Design outcomes

Primary

Measure	Time frame
Quitting smoking after 8 weeks of treatment by measuring lab values and expired breath CO levels	after 8 weeks of treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026